<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22264" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Open Angle Glaucoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahabadi</surname>
            <given-names>Navid</given-names>
          </name>
          <aff>A.T. Still University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeppieri</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>University Hospital of Udine, Italy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Navid Mahabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Zeppieri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22264.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Open-angle glaucoma (OAG) is a chronic, progressive, and irreversible multifactorial optic neuropathy. Characterized by an open angle of the anterior chamber, optic nerve head changes, and a gradual decline in peripheral vision followed by central visual field loss, OAG remains asymptomatic until advanced stages, emphasizing the critical need for early detection and management. Elevated intraocular pressure is a key risk factor for primary or secondary causes. Participating clinicians review the causes of OAG, pathophysiology, and the latest evidence-based strategies for evaluation and management.</p>
        <p>This course evaluates the complexities of OAG, and describes how early detection and management can help prevent irreversible vision loss and preserve patients' quality of life. Participants explore the multifactorial nature of OAG, including its pathophysiology, risk factors, and clinical manifestations. The latest evidence-based strategies for evaluating and managing OAG, focusing on lowering intraocular pressure, are thoroughly discussed. Additionally, the importance of early intervention and regular monitoring to prevent disease progression is emphasized. This course highlights the pivotal role of the interprofessional team in OAG management. Collaborative efforts among ophthalmologists, optometrists, primary care providers, and allied healthcare professionals enhance early detection, facilitate timely referrals, and ensure comprehensive patient care</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify risk factors and early signs of open-angle glaucoma during routine patient evaluations.</p></list-item><list-item><p>Differentiate between&#x000a0;open-angle glaucoma and other ocular conditions that may present with similar symptoms, ensuring accurate diagnosis and appropriate management.</p></list-item><list-item><p>Assess disease progression and treatment efficacy regularly through comprehensive ocular examinations and monitoring intraocular pressure levels.</p></list-item><list-item><p>Implement&#x000a0;care coordination amongst interprofessional teams to advance the treatment of open-angle glaucoma and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22264&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22264">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22264.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Glaucoma is a collection of diseases where increased&#x000a0;intraocular pressure (IOP) adversely impacts the optic nerve and, subsequently, the visual field.<xref ref-type="bibr" rid="article-22264.r1">[1]</xref> However, not all cases of glaucoma are associated with increased IOP. A subset includes similar optic nerve and visual field damage, known as normal pressure glaucoma.<xref ref-type="bibr" rid="article-22264.r2">[2]</xref> The collection of glaucomatous diseases is subdivided into open-angle and closed-angle glaucoma, both of which can have primary or secondary causes and can be of an iatrogenic or non-iatrogenic origin (see <bold>Image.&#x000a0;</bold>Classification of Open-Angle Glaucoma).</p>
        <p>Open-angle glaucoma (OAG) is a chronic, progressive, and irreversible multifactorial optic neuropathy characterized by an open angle of the anterior chamber, typical optic nerve head changes, retinal nerve fiber layer thinning, and progressive loss of peripheral vision (see <bold>Image.&#x000a0;</bold>Visual Field and Optical Coherence Tomography, OCT). Central visual field loss and blindness can occur in the advanced stages of glaucoma. IOP is an important risk factor and the target for therapy when treating patients.<xref ref-type="bibr" rid="article-22264.r3">[3]</xref></p>
        <p>The disease is usually bilateral, but asymmetry&#x000a0;depends on the etiology. Although increased IOP is a significant risk factor in developing glaucoma, IOP levels greater than 21 mm Hg do not necessarily cause glaucoma and optic nerve damage in all patients.<xref ref-type="bibr" rid="article-22264.r4">[4]</xref> Studies have shown asymptomatic individuals with ocular hypertension who maintain normal visual fields and healthy optic nerves.<xref ref-type="bibr" rid="article-22264.r5">[5]</xref></p>
      </sec>
      <sec id="article-22264.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Understanding the formation and drainage of aqueous humor is necessary to comprehend the etiology of OAG. The ciliary body continuously produces aqueous humor in the posterior chamber and drains it into the eye's anterior chamber. Most aqueous humor drainage occurs through the trabecular meshwork, and a minority of aqueous outflow is drained through the uveoscleral pathway.&#x000a0;</p>
        <p>Primary open-angle glaucoma (POAG) is the most common type, characterized by increased resistance to drainage in the trabecular meshwork. However, the drainage angle between the cornea and iris remains open.<xref ref-type="bibr" rid="article-22264.r6">[6]</xref>&#x000a0;Due to this blockage, the pressure in the eye gradually increases, resulting in optic nerve damage and progressive visual loss. Secondary OAG can have multiple etiologies but is far less common than POAG.&#x000a0;</p>
        <p>
<bold>Genetic&#x000a0;</bold>
</p>
        <p>Chromosome 1q24.3,&#x000a0;<italic toggle="yes">MYOC</italic>&#x000a0;gene: Myocilin is a cytoskeletal protein product of the&#x000a0;<italic toggle="yes">MYOC</italic>&#x000a0;gene, implicated in cases of hereditary juvenile OAG and adult OAG. Myocilin is a cytoskeletal protein expressed in the trabecular meshwork and is also known as trabecular meshwork glucocorticoid-inducible response protein.<xref ref-type="bibr" rid="article-22264.r7">[7]</xref>&#x000a0;</p>
        <p>Chromosome 5q22.1,&#x000a0;<italic toggle="yes">WDR36</italic>&#x000a0;gene: The&#x000a0;<italic toggle="yes">WDR36</italic>&#x000a0;protein is a member of the WD repeat protein family and is implicated in adult-onset POAG. This protein functions in ribosomal ribonucleic acid processing, p53 stress-pathway response, cell cycle progression, signal transduction, apoptosis, and gene regulation.&#x000a0;<italic toggle="yes">WDR36</italic>&#x000a0;protein is expressed in the lens, iris, sclera, ciliary muscles, ciliary body, trabecular meshwork, retina, and optic nerve in the eye. The protein is also expressed outside the eye in the human heart, placenta, liver, skeletal muscle, kidney, and pancreas. Four mutations in&#x000a0;<italic toggle="yes">WDR36</italic>&#x000a0;at the&#x000a0;<italic toggle="yes">GLC1G</italic>&#x000a0;locus (<italic toggle="yes">N355S</italic>,&#x000a0;<italic toggle="yes">A449T</italic>,&#x000a0;<italic toggle="yes">R529Q</italic>, and&#x000a0;<italic toggle="yes">D658G</italic>) have been identified, with a study implicating the gene in approximately 6% of patients with POAG. However, results from a recent 2017 Chinese study repudiated this claim by showing that the association between&#x000a0;<italic toggle="yes">WDR36</italic>&#x000a0;and POAG is inconsistent across populations and calls for more data supporting the&#x000a0;<italic toggle="yes">WDR36&#x000a0;</italic>protein's role in POAG.<xref ref-type="bibr" rid="article-22264.r8">[8]</xref><xref ref-type="bibr" rid="article-22264.r9">[9]</xref></p>
        <p>Chromosome 7q31,&#x000a0;<italic toggle="yes">CAV1/CAV2</italic>&#x000a0;genes:&#x000a0;<italic toggle="yes">CAV1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">CAV2</italic>&#x000a0;are protein members of the caveolin family that are involved in the formation of caveolae-invaginations of the plasma membrane in areas that are rich in cholesterol during transcytosis. This gene is associated with POAG susceptibility in populations of European and East Asian ancestry.&#x000a0;<italic toggle="yes">CAV1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">CAV2</italic>&#x000a0;are expressed in most human cell types, including tissues such as the scleral spur cells, trabecular meshwork, and retinal ganglion cells. In vitro studies of&#x000a0;<italic toggle="yes">CAV1</italic>&#x000a0;showed consistent upregulation in the trabecular meshwork after one hour of increased IOP.<xref ref-type="bibr" rid="article-22264.r10">[10]</xref><xref ref-type="bibr" rid="article-22264.r11">[11]</xref></p>
        <p>Chromosome 9p21,&#x000a0;<italic toggle="yes">CDKN2B-AS1</italic>&#x000a0;gene:&#x000a0;<italic toggle="yes">CDKN2B-AS1</italic>&#x000a0;is a cyclin-dependent kinase inhibitor 2B antisense noncoding ribonucleic acid that regulates cyclin-dependent kinase inhibitor 2A and 2B in the cell cycle.<xref ref-type="bibr" rid="article-22264.r12">[12]</xref>&#x000a0;A United States-based observational case study found that this region modifies optic nerve vulnerability to glaucomatous change. Single nucleotide polymorphism (SNP) in this gene is thought to be implicated in POAG by causing RGCs to undergo apoptosis during their quiescent post-mitotic state.<xref ref-type="bibr" rid="article-22264.r13">[13]</xref><xref ref-type="bibr" rid="article-22264.r14">[14]</xref>&#x000a0;</p>
        <p>Chromosome 10p13,&#x000a0;<italic toggle="yes">OPTN</italic>&#x000a0;gene: Optineurin is the coiled-coil protein product implicated in adult-onset POAG and normal-tension glaucoma. Optineurin is involved in various cellular functions, including apoptosis, cellular morphogenesis, inflammation, vasoconstriction, membrane protein trafficking, vesicular trafficking, and transcription activation.<xref ref-type="bibr" rid="article-22264.r15">[15]</xref></p>
        <p>Chromosome 15q24.1,&#x000a0;<italic toggle="yes">LOXL1</italic>&#x000a0;gene: Lysyl oxidase-like 1 gene codes for an extracellular copper-dependent amine oxidase enzyme that catalyzes the first step in crosslinking collagen and elastin in the extracellular matrix and is implicated in cases of pseudoexfoliation syndrome. SNP in the&#x000a0;<italic toggle="yes">LOXL1</italic>&#x000a0;gene is associated with excessive levels of crosslinked amyloid-like fibrillar glycoproteins that deposit in the anterior segment and are more common in Scandinavian populations.<xref ref-type="bibr" rid="article-22264.r16">[16]</xref><xref ref-type="bibr" rid="article-22264.r17">[17]</xref>&#x000a0;SNPs in the&#x000a0;<italic toggle="yes">LOXL1</italic>&#x000a0;gene can present as exfoliation glaucoma as the first signs of a more systemic severe condition that implicates multiple tissues with the expression of this enzyme, including the liver, kidney, and gallbladder.<xref ref-type="bibr" rid="article-22264.r18">[18]</xref><xref ref-type="bibr" rid="article-22264.r19">[19]</xref></p>
        <p>Several study results (based on whole-exome sequencing using gene-based and single-variant analyses) have revealed more than 40 new previously unreported genes associated with glaucoma phenotypes.<xref ref-type="bibr" rid="article-22264.r20">[20]</xref>&#x000a0;Understanding this disease's genetic and molecular mechanisms is crucial to developing new drug targets.<xref ref-type="bibr" rid="article-22264.r21">[21]</xref><xref ref-type="bibr" rid="article-22264.r22">[22]</xref></p>
      </sec>
      <sec id="article-22264.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Glaucoma affects about 70 million people worldwide and is the second leading cause of blindness globally. Of the 70 million individuals affected by glaucoma, 74% have OAG; in the United States (US), nearly 80% of all glaucoma is OAG. A recent meta-analysis showed that the estimated number of individuals with POAG worldwide is about 68.56 million, with more than 50% from Africa and Asia.<xref ref-type="bibr" rid="article-22264.r23">[23]</xref>&#x000a0;Nearly 10% of all patients with glaucoma are blind bilaterally; bilateral blindness due to OAG has been estimated to affect 5.9 million people in 2020. At least 2.7 million people &#x02265;40 years are diagnosed with glaucoma in the US, and the number of patients with all forms of glaucoma worldwide is projected to rise. The highest prevalence of OAG is found in African-American populations. Glaucoma is the leading cause of blindness in African Americans, with prevalence in Latin American and Chinese individuals approaching in older patient populations. Women are disproportionately affected by all forms of glaucoma, comprising approximately 55.4% of all cases of OAG.</p>
        <p>Longevity also plays a role because glaucoma primarily affects older populations. The longevity factor should be considered in the epidemiology of glaucoma, as women and individuals in developed countries have greater longevity than men and individuals in non-developed countries. In 2020, OAG was projected to have the highest prevalence rate in Europe, followed by China and India.<xref ref-type="bibr" rid="article-22264.r24">[24]</xref><xref ref-type="bibr" rid="article-22264.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Risk Factors:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Older age (African American, 40+ years; Caucasians, 65+ years)&#x000a0;<xref ref-type="bibr" rid="article-22264.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Race (African-American, Afro-Caribbean, and West African patients have a 4-fold increased risk of developing OAG)<xref ref-type="bibr" rid="article-22264.r26">[26]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Family history (eg, the Rotterdam Eye study found a 9.2 times higher risk of developing OAG if first-degree relatives had glaucoma)<xref ref-type="bibr" rid="article-22264.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Elevated IOP&#x000a0;<xref ref-type="bibr" rid="article-22264.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Myopia (eg, results from studies have reported an increased risk of glaucoma of up to 20% for each diopter increase in myopia)&#x000a0;<xref ref-type="bibr" rid="article-22264.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Increased cup-to-disc ratio&#x000a0;<xref ref-type="bibr" rid="article-22264.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Disc hemorrhage&#x000a0;<xref ref-type="bibr" rid="article-22264.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Thin central corneal thickness&#x000a0;<xref ref-type="bibr" rid="article-22264.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Low ocular perfusion pressure&#x000a0;<xref ref-type="bibr" rid="article-22264.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Low blood pressure (systolic and diastolic)<xref ref-type="bibr" rid="article-22264.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>High blood pressure (systemic arterial hypertension has been associated with but is not a confirmed risk factor for OAG)<xref ref-type="bibr" rid="article-22264.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Type 2 diabetes mellitus&#x000a0;<xref ref-type="bibr" rid="article-22264.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>High pattern standard deviation on visual fields&#x000a0;<xref ref-type="bibr" rid="article-22264.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Migraine or vasospasm&#x000a0;<xref ref-type="bibr" rid="article-22264.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Low intracranial (cerebral spinal fluid) pressure&#x000a0;<xref ref-type="bibr" rid="article-22264.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Oral contraceptive pill&#x000a0;<xref ref-type="bibr" rid="article-22264.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Lifestyle risk factors include smoking, obesity, alcohol, anxiety, stress, and sleep apnea&#x000a0;<xref ref-type="bibr" rid="article-22264.r41">[41]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Retinal Ganglion Cells</bold>
</p>
        <p>The exact cause of glaucoma is not fully known, but the underlying pathology lies in the apoptosis of retinal ganglion cells.<xref ref-type="bibr" rid="article-22264.r7">[7]</xref>&#x000a0;Retinal ganglion cells (RGC) are the third class of photoreceptors recently noted in scientific literature for their intrinsic photosensitivity. RGCs form functional microcircuits with rods, cones, amacrine cells, and bipolar cells that help transmit image-forming and non-image-forming information to the brain. RGC axons target the suprachiasmatic nucleus, intergeniculate leaflet, olivary pretectal nucleus, ventral division of the lateral geniculate nucleus, and the preoptic area.&#x000a0;</p>
        <p>RGCs play a role in modulating circadian rhythm, releasing melatonin, regulating pupil size, and forming relays in on-off retina centers.<xref ref-type="bibr" rid="article-22264.r42">[42]</xref>&#x000a0;RGC axons remain unmyelinated until they have passed through the lamina cribrosa and converged to form the optic nerve.</p>
        <p>After passing through the lamina cribrosa, oligodendrocytes myelinate the axons of the RGCs. Iatrogenically induced ocular hypertension in mice, cats, and monkeys has shown blockade of orthograde and retrograde axonal transport, integral in transporting growth factors such as brain-derived neurotrophic factors. Regardless of whether IOP is elevated, normal, or decreased, the death of RGCs underlies glaucoma pathology.<xref ref-type="bibr" rid="article-22264.r43">[43]</xref><xref ref-type="bibr" rid="article-22264.r44">[44]</xref></p>
        <p>
<bold>Lamina Cribrosa</bold>
</p>
        <p>The lamina cribrosa is a sieve-like fenestration at the back of the sclera that allows for a conglomeration of retinal axons and blood vessels to exit the posterior of the eye. Changes in the three-dimensional structure of the lamina cribrosa have been implicated in the pathogenesis of glaucomatous optic atrophy.<xref ref-type="bibr" rid="article-22264.r45">[45]</xref>&#x000a0;The superior and inferior channels of the lamina cribrosa contain larger pores and thinner connective tissue support for the passage of nerve-fiber bundles than the nasal and temporal parts of the lamina. The most common pattern of glaucomatous optic nerve thinning occurs at the inferior and superior portions of the optic nerve. Also, the superior and inferior laminar zones of the lamina cribrosa are where the arcuate area ganglion cell axons travel, and these axons are the most susceptible to glaucomatous damage.</p>
        <p>Mechanical damage to axons and the prevention of essential trophic factors, such as the brain-derived neurotrophic factor, being appropriately delivered is conducive to the disease process. Results from studies show that statistically significant depth variability exists among the superior and inferior lamina cribrosa of healthy patients and those with OAG. Patients with OAG have greater depth at the optic cup floor, possibly due to increased IOP pressure. One study examined the lamina cribrosa using Heidelberg retina tomograph and found greater topographic variability and "spikiness" when looking at the lamina cribrosa of patients with OAG; this is most likely a sign of fragility in the lamina, as increased spikiness is inversely related to Humphrey mean deviation (<italic toggle="yes">P&#x000a0;</italic>&#x0003c; 0.05), and cup-disc ratio (<italic toggle="yes">P</italic>&#x000a0;&#x0003c; 0.004) and was directly related to nerve fiber layer thickness (<italic toggle="yes">P&#x000a0;</italic>&#x0003c; 0.005).<xref ref-type="bibr" rid="article-22264.r46">[46]</xref><xref ref-type="bibr" rid="article-22264.r47">[47]</xref></p>
        <p>
<bold>Elevated Intraocular Pressure</bold>
</p>
        <p>High IOP is an important risk factor for glaucoma progression. Elevated IOP is the most studied and modifiable risk factor that causes OAG. When IOP rises above 21 mm Hg, a significant risk of developing visual field loss exists (with only small increases in IOP), especially if IOP rises above 26 mm Hg to 30 mm Hg. The high fluctuation of IOP may also lead to glaucoma progression. Reduction of IOP leads to less progression or stabilization of the glaucomatous optic nerve and visual field changes. About 40% to 50% of all OAG cases have IOP below 22 mm Hg in a single screening.<xref ref-type="bibr" rid="article-22264.r35">[35]</xref><xref ref-type="bibr" rid="article-22264.r48">[48]</xref></p>
        <p>
<bold>Aqueous Outflow</bold>
</p>
        <p>The 2 main proposed mechanisms by which an elevated IOP is thought to contribute to glaucomatous damage include vascular dysfunction resulting in ischemia to the optic nerve&#x000a0;<xref ref-type="bibr" rid="article-22264.r49">[49]</xref>&#x000a0;and mechanical dysfunction due to compression of the axons.<xref ref-type="bibr" rid="article-22264.r50">[50]</xref>&#x000a0;When OAG in a patient is attributed to elevated IOP, the cause of this increase in IOP is commonly thought to occur due to dysfunction in aqueous outflow through the trabecular meshwork of the eye.<xref ref-type="bibr" rid="article-22264.r51">[51]</xref>&#x000a0;This may occur as a result of partial obstruction due to foreign material (eg, accumulated mucopolysaccharides in the trabecular meshwork), a reduction in the number of trabecular endothelial cells, a decreased density of trabecular pores, number of vacuoles, or size of the inner wall endothelium of the canal of Schlemm, loss of phagocytic activity, or dysfunction in the neurological feedback loop involved in drainage of aqueous humor.&#x000a0;</p>
        <p>Other proposed mechanisms for obstruction of aqueous humor outflow include oxidative damage to the meshwork, abnormal corticosteroid metabolism, adrenergic dysfunction, or an immunological process. Unlike angle-closure glaucoma, the drainage angle between the iris and cornea remains open in OAG. Specific individuals may have a genetic predisposition&#x000a0;<xref ref-type="bibr" rid="article-22264.r52">[52]</xref>&#x000a0;to cell death of individual axons in the eye, resulting in the release of potentially cytotoxic substances such as glutamate, calcium, nitric oxide, and free radicals, as well as the apoptosis of neighboring cells.</p>
      </sec>
      <sec id="article-22264.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Early in the disease process, glaucomatous optic nerve atrophy can present with thinning and atrophy of the retinal ganglion cell layer and, thus, thinning of the nerve fiber layer above the ganglion cells.<xref ref-type="bibr" rid="article-22264.r53">[53]</xref> The nerve fiber layer consists of the unmyelinated ganglion cell axons, which shrink concomitantly.<xref ref-type="bibr" rid="article-22264.r54">[54]</xref> In more advanced glaucomatous optic nerve atrophy, cupping of the optic nerve and atrophy of the ganglion cell and nerve fiber layers is prevalent. As the ganglion cells deteriorate, the structural integrity of the nerve is compromised. Increased IOP can push into the optic nerve and cause the visible phenomenon of cupping. Retinal ganglion cell loss also leads to increased space and widening of the subdural optic nerve space (see&#x000a0;<bold>Image.&#x000a0;</bold>Glaucomatous Optic Nerve Head With Inferotemporal Retinal Nerve Fiber Layer Defect).<xref ref-type="bibr" rid="article-22264.r55">[55]</xref></p>
      </sec>
      <sec id="article-22264.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>In OAG, particulate matter can lodge into the fine openings in the trabecular meshwork (TM) and increase the passive resistance to aqueous humor drainage. Different substances can disrupt the flow of aqueous across the TM, which include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lens proteins: During cataract surgery, high-molecular-weight lens proteins produced by phacolysis can lodge into the trabecular meshwork and increase drainage resistance.<xref ref-type="bibr" rid="article-22264.r56">[56]</xref><xref ref-type="bibr" rid="article-22264.r57">[57]</xref></p>
          </list-item>
          <list-item>
            <p>Red blood cells: In the event of a traumatic injury to the eye, senescent red blood cells&#x000a0;are lodged in the trabecular meshwork, a variant of&#x000a0;OAG known as "Ghost cell glaucoma."<xref ref-type="bibr" rid="article-22264.r58">[58]</xref></p>
          </list-item>
          <list-item>
            <p>Pigment granules: Pigment from the epithelium of the iris can detach and become lodged in the fine trabecular meshwork, as seen in pigmentary glaucoma&#x000a0;<xref ref-type="bibr" rid="article-22264.r59">[59]</xref>&#x000a0;and pigment dispersion syndrome.<xref ref-type="bibr" rid="article-22264.r56">[56]</xref><xref ref-type="bibr" rid="article-22264.r60">[60]</xref></p>
          </list-item>
          <list-item>
            <p>Pseudoexfoliation syndrome: Deposits of white dandruff-like material on the anterior lens surface, iris, and anterior chamber structures.<xref ref-type="bibr" rid="article-22264.r61">[61]</xref></p>
          </list-item>
          <list-item>
            <p>Tumor debris: Necrotic tumor debris from necrotic tumors can also clog the trabecular meshwork in a variant known as melanomalytic glaucoma.<xref ref-type="bibr" rid="article-22264.r62">[62]</xref></p>
          </list-item>
          <list-item>
            <p>Corticosteroids: Steroid therapy of any kind can contribute to elevated IOP; however, topical eye and periocular steroids are most likely to increase IOP.<xref ref-type="bibr" rid="article-22264.r26">[26]</xref><xref ref-type="bibr" rid="article-22264.r63">[63]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>OAG is often asymptomatic in its early stages; a thorough history and eye exam are instrumental in detecting the disease early (see&#x000a0;<bold>Image.&#x000a0;</bold>Glaucoma Field Changes in Left Eye).<xref ref-type="bibr" rid="article-22264.r64">[64]</xref>&#x000a0;Early changes in OAG involve a loss of peripheral vision that the patient is usually unaware of until 40% of their nerve fibers are compromised; only then do they start to notice having &#x0201c;tunnel vision.&#x0201d; Visual field defects typically occur after asymptomatic retinal nerve fiber layer thinning and optic nerve cupping (see&#x000a0;<bold>Image.&#x000a0;</bold>A Cup-to-Disk Ratio of .75 of the Optic Nerve). Patients do not avert glaucomatous signs and symptoms, unlike maculopathies and cataracts that lead to decreased visual acuity.</p>
        <p>Older patients might give clues about their history of losing peripheral vision by admitting to difficulties driving or running into objects around the home more frequently. Primary care patients with the above risk factors should undergo direct ophthalmoscopy to visualize the optic disc.<xref ref-type="bibr" rid="article-22264.r65">[65]</xref>&#x000a0;Visualization of the optic disc can provide reliable diagnostic information as it shows changes before the visual field deficits are symptomatic. OAG is often bilateral, and the 2 optic discs can be compared to one another as a useful metric, but the damage can also be asymmetric.</p>
        <p>Primary care clinicians should refer patients to an ophthalmologist in the presence of the following risk factors, clinical findings, or symptoms that are suggestive of glaucoma:</p>
        <list list-type="bullet">
          <list-item>
            <p>A previous ocular history, such as the history of eye pain or redness, headaches, uveitis, diabetic retinopathy, cataracts, vascular occlusions, or multicolored halos</p>
          </list-item>
          <list-item>
            <p>African-American race&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Refractive error</p>
          </list-item>
          <list-item>
            <p>Chronic use of topical or systemic corticosteroids</p>
          </list-item>
          <list-item>
            <p>Ocular surgery like photocoagulation or refractive procedures, cataract surgery, glaucoma surgery, and systemic surgery/ medications</p>
          </list-item>
          <list-item>
            <p>Head or ocular trauma</p>
          </list-item>
          <list-item>
            <p>Certain medications, such as hypertensive medications that may influence IOP or systemic/topical steroids</p>
          </list-item>
          <list-item>
            <p>Medical history of diabetes mellitus, migraine headaches, hypertension, vasospasm, cardiovascular disease, breathlessness, cardiac arrhythmia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Family history (eg, first-degree relative with glaucoma, especially significant if this is a sibling) that would place them at a greater risk of developing OAG</p>
          </list-item>
          <list-item>
            <p>Old medical documentation of IOP, optic disc, visual field, and others</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>OAG can be clinically evaluated using a variety of diagnostic tools, but the following triad is the cornerstone of diagnosis:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Optic disc or retinal nerve fiber layer changes</p>
          </list-item>
          <list-item>
            <p>Visual field changes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Elevated IOP&#x000a0;<xref ref-type="bibr" rid="article-22264.r66">[66]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Optic Nerve</bold>
</p>
        <p>The optic nerve should be evaluated using a slit lamp and 90D or 78D lens so that the three-dimensional features of the optic nerve are appreciated. The inferior neuroretinal rim (NRR) is the thickest, followed by superior, nasal, and temporal NRR; this is called the ISNT rule.<xref ref-type="bibr" rid="article-22264.r67">[67]</xref>&#x000a0;In OAG, the superior and inferior NRR are thinned, breaking the ISNT rule. The optic cup should be determined by its contour and not color. A recent <italic toggle="yes">Journal of the Americal Medical Association</italic> Rational Clinical Examination systematic review of primary OAG diagnosis found that the risk of glaucoma was highest when an examination revealed an increased cup-disk ratio (CDR), CDR asymmetry, disc hemorrhage, or elevated IOP.<xref ref-type="bibr" rid="article-22264.r68">[68]</xref></p>
        <p>Typical optic nerve head changes in OAG include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse or focal narrowing (notching/shelving) of the NRR precisely at the superior or inferior part of the optic disc</p>
          </list-item>
          <list-item>
            <p>Symmetrically enlarged cup-to-disc ratios greater than 0.5</p>
          </list-item>
          <list-item>
            <p>Increased vertical cup-to-disc ratio and thinning of NRR</p>
          </list-item>
          <list-item>
            <p>Asymmetry of CDR of 0.2 or more</p>
          </list-item>
          <list-item>
            <p>Hemorrhage at or around the optic disc</p>
          </list-item>
          <list-item>
            <p>Peripapillary atrophy</p>
          </list-item>
          <list-item>
            <p>Baring of circumlinear vessels (the gap between the superficial vessels and disc margin)</p>
          </list-item>
          <list-item>
            <p>Bayonetting of vessels (the vessel first goes back and then climbs along the wall of the deep cup and then angles again on the disc margin)</p>
          </list-item>
          <list-item>
            <p>Very deep (excavated) cup with bean-pot cupping and laminar dot sign</p>
          </list-item>
          <list-item>
            <p>Nasalization of optic disc vessels</p>
          </list-item>
          <list-item>
            <p>Diffuse or focal (arcuate) thinning/defect of the retinal nerve fiber layer contiguous with an area of NRR-notch</p>
          </list-item>
          <list-item>
            <p>The NRR is typically pink and not pale in OAG. The pallor of the NRR usually denotes an atrophic optic nerve, as seen in primary angle closure glaucoma.</p>
          </list-item>
        </list>
        <p>
<bold>Visual Field</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Perimetry, also known as visual field testing, is an important diagnostic tool that maps out the patient&#x02019;s visual field on a printout, making it helpful and necessary in diagnosing and managing OAG. The testing provides a baseline visual field for glaucoma suspects and confirmed OAG cases so clinicians can track disease progression. To make a diagnosis of acquired glaucomatous visual field defect, Hoddap&#x02013;Parrish&#x02013;Anderson criteria are used:</p>
          </list-item>
          <list-item>
            <p>Glaucoma hemifield test outside normal limits on at least 2 fields.</p>
          </list-item>
          <list-item>
            <p>A cluster of 3 or more non-edge points in a location typical for glaucoma, all of which are depressed on the pattern deviation plot at a&#x000a0;<italic toggle="yes">P&#x000a0;</italic>&#x0003c;5% and one of which is depressed at a&#x000a0;<italic toggle="yes">P</italic>&#x000a0;&#x0003c;1% on 2 consecutive fields.</p>
          </list-item>
          <list-item>
            <p>A corrected pattern standard deviation that occurs in less than 5% of normal fields on 2 consecutive fields.<xref ref-type="bibr" rid="article-22264.r69">[69]</xref></p>
          </list-item>
        </list>
        <p>Static automated threshold perimetry is used with white stimulus on a white background. Most studies used the Humphrey Field Analyzer, but other perimeters like Octopus have also been used successfully. Non-conventional perimetry like SWAP (short-wavelength automated perimetry using blue stimulus on yellow background),<xref ref-type="bibr" rid="article-22264.r70">[70]</xref>&#x000a0;pulsar perimetry,<xref ref-type="bibr" rid="article-22264.r71">[71]</xref><xref ref-type="bibr" rid="article-22264.r72">[72]</xref>&#x000a0;rarebit,<xref ref-type="bibr" rid="article-22264.r73">[73]</xref><xref ref-type="bibr" rid="article-22264.r74">[74]</xref>&#x000a0;Matrix,<xref ref-type="bibr" rid="article-22264.r75">[75]</xref>&#x000a0;and frequency-doubling technology&#x000a0;<xref ref-type="bibr" rid="article-22264.r76">[76]</xref>&#x000a0;have been proposed in earlier studies for the detection of early glaucoma visual field loss, however, tend not to be used in routine clinical practice.</p>
        <p>The visual field must be reliable, and defects should be repeatable on at least 2 fields. When treating patients long-term, it is preferable to use the same machine, the same degree of field, and protocol (eg, 24-2, 30-3, or 10-2) to compare the fields to note for progression or stability. At least 40% to 50% ganglion cell loss is needed to reliably show visual field defects in threshold perimetry.<xref ref-type="bibr" rid="article-22264.r77">[77]</xref><xref ref-type="bibr" rid="article-22264.r78">[78]</xref>&#x000a0;Structural changes of the optic nerve and retinal nerve fiber layer (RNFL) tend to occur earlier than functional change (visual field loss) in most patients with OAG;</p>
        <p>this is relevant to the concept of preperimetric glaucoma, which is defined as &#x02018;the presence of characteristic glaucomatous changes in the optic disc and increased vulnerability to damage in the RNFL, without the presence of visual field defects detectable with standard automated perimetry.<xref ref-type="bibr" rid="article-22264.r79">[79]</xref>&#x000a0;For patients with risk factors, suspect optic discs, and/or ocular hypertension (OHT), periodic visual field and OCT testing are recommended to detect early visual field defects and changes to determine whether therapy is needed.</p>
        <p>Typical visual field changes in OAG include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased variability of responses in an area that later developed field defects</p>
          </list-item>
          <list-item>
            <p>Asymmetry of the visual field between the eyes</p>
          </list-item>
          <list-item>
            <p>Paracentral scotoma- commonly superonasal</p>
          </list-item>
          <list-item>
            <p>Roenne&#x02019;s nasal step- an area of depression above or below the horizontal meridian on the nasal side&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Temporal wedge</p>
          </list-item>
          <list-item>
            <p>Sickle-shaped (Seidel) scotoma</p>
          </list-item>
          <list-item>
            <p>Bjerrum scotoma or arcuate scotoma</p>
          </list-item>
          <list-item>
            <p>Annular or ring scotoma when arcuate scotoma is present on both above and below the horizontal meridian</p>
          </list-item>
          <list-item>
            <p>General constriction of peripheral field</p>
          </list-item>
          <list-item>
            <p>A temporal island of the visual field</p>
          </list-item>
        </list>
        <p>
<bold>Intraocular Pressure</bold>
</p>
        <p>IOP is measured with tonometry;<xref ref-type="bibr" rid="article-22264.r80">[80]</xref>&#x000a0;several different tonometers are used.<xref ref-type="bibr" rid="article-22264.r81">[81]</xref>&#x000a0;The gold standard remains to be Goldmann applanation tonometry.<xref ref-type="bibr" rid="article-22264.r82">[82]</xref>&#x000a0;When determining the IOP of a patient using tonometry, certain variables must be considered. Tonometry measurements can, for example, vary between examiners by approximately 10% per individual, translating to a difference in IOP measurement of 1 mm Hg to 2 mm Hg (see&#x000a0;<bold>Image.&#x000a0;</bold>Goldmann Applanation Tonometer [GAT] Procedure).<xref ref-type="bibr" rid="article-22264.r83">[83]</xref></p>
        <p>An individual&#x02019;s corneal thickness measured with pachymetry or diurnal variations of IOP (eg, higher IOP in early morning hours or other times of the day or variability in the time of day of maximal IOP between patients)<xref ref-type="bibr" rid="article-22264.r84">[84]</xref>&#x000a0;can also have a tremendous effect on the accuracy of IOP measurements. Study results have shown that IOP is overestimated in individuals with thick corneas while underestimated in those with thinner corneas.<xref ref-type="bibr" rid="article-22264.r85">[85]</xref>&#x000a0;Multiple measurements should be taken and correlated with optic nerve and visual field examinations when a patient is suspected of elevated IOP.</p>
        <p>If previous tonometry measurements are available, they should be reviewed and compared to the most recent ones. Also, the IOP may be different on different days, and different instruments may capture different values of IOP. If a difference of 3 mm Hg or more is noted between the 2 eyes, there is an increased suspicion of glaucoma. Clinicians should expect approximately 10% variation between individual and repeat measurements over 2 to 3 occasions before deciding on the treatment.</p>
        <p>Elevated IOP is an important and modifiable risk factor; however, it is not a diagnostic factor for OAG. An ophthalmologist should check the patient&#x02019;s IOP using applanation tonometry, remaining aware that the applanation tonometry test causes patients to squeeze their eyes and elevate their pressure readings. Normal IOP should range between 12 mm Hg and 21 mm Hg. Approximately 75% of patients with elevated IOP never develop glaucomatous optic nerve atrophy or visual field deficits. When a patient has recorded a reliably high IOP reading above 21 mm Hg, they are deemed patients with glaucoma or patients with ocular hypertension.<xref ref-type="bibr" rid="article-22264.r35">[35]</xref><xref ref-type="bibr" rid="article-22264.r86">[86]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Gonioscopy</bold>
</p>
        <p>OAG is a diagnosis of exclusion, and other ocular emergencies, such as closed-angle glaucoma, must be ruled out.<xref ref-type="bibr" rid="article-22264.r87">[87]</xref>&#x000a0;Gonioscopy determines whether the diagnosis is considered &#x0201c;open&#x0201d; or &#x0201c;closed&#x0201d; angle glaucoma. Gonioscopy is an acquired skill that allows the ophthalmologist to visualize the angle between the cornea and iris and determine if it is open. The angle between the iris and cornea should be 20&#x000b0; to 45&#x000b0; to be considered &#x0201c;open&#x0201d; so that aqueous humor can circumvent the posterior chamber to the anterior chamber.<xref ref-type="bibr" rid="article-22264.r35">[35]</xref>&#x000a0;</p>
        <p>
<bold>Optical Coherence Tomography&#x000a0;</bold>
</p>
        <p>Optical coherence tomography (OCT) is a diagnostic imaging modality that provides high-resolution cross-sectional imaging of the retina, optic nerve, and anterior segment. Low-coherence infrared light is directed toward the back of the eye, and the path of scattered photons helps recreate an image of the retina. OCT is highly reproducible and is widely used as an adjunct in routine glaucoma patient management. Peripapillary RNFL analysis (see&#x000a0;<bold>Image.&#x000a0;</bold>Normal Visual Field and Optical Coherence Tomography [OCT] Results) can show thinning in this layer. As the most commonly used scanning protocol for glaucoma diagnosis, it samples RGCs from the entire retina.<xref ref-type="bibr" rid="article-22264.r88">[88]</xref>&#x000a0;Some of the drawbacks included variability in ONH morphology from patient to patient. The macular thickness is proposed as a means of glaucoma detection, given that 50% of RGCs are found in the macula, and RGC bodies are thicker than their axons and potentially easier to detect.<xref ref-type="bibr" rid="article-22264.r89">[89]</xref>&#x000a0;RNFL, macular thickness measurements, and visual field results are key in managing cases.</p>
        <p>
<bold>Corneal Photokeratoscopy</bold>
</p>
        <p>Corneal photokeratoscopy, or corneal topography, is a potential biological marker to monitor patients with primary OAG. Preliminary results have shown a forward shift of the posterior and anterior corneal surfaces; this is correlated with more advanced stages of functional damage, indicating a link between corneal structural changes and the duration and intensity of elevated IOP. Further studies are needed to validate this marker in patients with POAG.<xref ref-type="bibr" rid="article-22264.r57">[57]</xref></p>
      </sec>
      <sec id="article-22264.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of OAG treatment is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Preventing the progression of optic nerve head changes</p>
          </list-item>
          <list-item>
            <p>Preventing deterioration of the visual field</p>
          </list-item>
        </list>
        <p>The concept of target IOP was introduced to achieve this goal.<xref ref-type="bibr" rid="article-22264.r90">[90]</xref>&#x000a0;Below a certain upper limit of IOP, it is estimated that the visual field, the optic nerve head, and RNFL parameters will not deteriorate. This helps to maintain a patient&#x02019;s quality of life.&#x000a0;</p>
        <p>
<bold>Glaucoma Medications</bold>
</p>
        <p>Debate exists over the optimal time to initiate treatment of OAG, with some clinicians initiating treatment of IOP when it reaches above only 21 mm Hg and others reserving treatment either until evidence of optic nerve or RNFL damage or if the patient is at high risk of damage or progression of OAG.&#x000a0;</p>
        <p>Treatment should be initiated if signs of damage as a result of OAG are evident (eg, disc hemorrhage, nerve fiber layer defects, asymmetric cupping, vertical vocalization, or notching of the cup) or if symptoms of elevated IOP are present (eg, halos, blurred vision, pain, IOP consistently above 28 mm Hg to 30 mm Hg) due to the high risk of optic nerve damage in the setting of elevated IOP. Some clinicians begin a monocular trial with medications only in 1 eye to assess the chosen medications&#x02019; effectiveness and side effects before treating both eyes. However, different eyes might respond differently to the same drug, asymmetric IOP fluctuation may occur, and the drug may have a contralateral effect.</p>
        <p>A target IOP should be set depending on the severity of structural and functional damage, baseline IOP, age, race, family history, corneal thickness, hysteresis, and other risk factors.<xref ref-type="bibr" rid="article-22264.r91">[91]</xref>&#x000a0;Follow-up should also be scheduled based on the level of success in IOP reduction between visits (eg, more frequent follow-up with slower progression in treatment response) and the severity of optic nerve damage or visual field loss. Treatment should be individualized, considering the risk factors, systemic complications of medication use, the patient&#x02019;s life expectancy, medical history, concomitant conditions, and desire to comply with treatment. The target IOP should be revised based on the behavior of optic nerve head damage and visual function.</p>
        <p>If IOP, visual field, or optic nerve inflammation worsens while the patient is on medical therapy, compliance to treatment must be checked.<xref ref-type="bibr" rid="article-22264.r92">[92]</xref>&#x000a0;Systemic factors, including diabetes, smoking, and nocturnal hypotension, should be controlled. The managing clinician should confirm with the patient which drops are used and how many times the drops are applied daily. Closing eyelids after administration of drops with nasolacrimal duct occlusion may prevent systemic absorption of the topical medication.</p>
        <p>
<bold>Topical medications</bold>
</p>
        <p>Prostaglandin analogs: Reduces IOP 25% to 33% by increasing the uveoscleral outflow of the aqueous humor (AH).<xref ref-type="bibr" rid="article-22264.r93">[93]</xref>&#x000a0;The usual dose is daily. Side effects include lengthening of eyelashes, pigmentation of lids or iris, exacerbation of uveitis or herpetic infection, and cystoid macular edema; it is preferred as initial therapy. The types of prostaglandin analogs used in routine clinics include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Latanoprost&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Travoprost</p>
          </list-item>
          <list-item>
            <p>Bimatoprost&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tafluprost</p>
          </list-item>
          <list-item>
            <p>Latanoprostene Bunod: This has nitric oxide-donating properties.</p>
          </list-item>
        </list>
        <p>Adrenergic agents: Reduces IOP 20% to 25% by decreasing AH production and increasing uveoscleral outflow.<xref ref-type="bibr" rid="article-22264.r94">[94]</xref>&#x000a0;Brimonidine may cause allergic blepharoconjunctivitis and apnea, lethargy, or bradycardia in children. These agents include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Brimonidine</p>
          </list-item>
          <list-item>
            <p>Apraclonidine</p>
          </list-item>
        </list>
        <p>Beta-blockers: Reduces IOP 20% to 25% by decreasing the production of AH.<xref ref-type="bibr" rid="article-22264.r95">[95]</xref>&#x000a0;Non-selective beta-blockers should be avoided in chronic obstructive pulmonary disease and asthma. Other contraindications include heart block, hypotension, and bradycardia. These drops include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-selective (may have effects on other receptors in the body and thus may have more side effects in some patients)</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Timolol</p>
              </list-item>
              <list-item>
                <p>Carteolol</p>
              </list-item>
              <list-item>
                <p>Levobunolol</p>
              </list-item>
              <list-item>
                <p>Metipranolol</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Selective (show better safety profile about respiratory symptoms)&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Betaxolol</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Carbonic anhydrase inhibitor: Reduces IOP by 15% to 20%, decreasing the production of AH.<xref ref-type="bibr" rid="article-22264.r96">[96]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dorzolamide</p>
          </list-item>
          <list-item>
            <p>Brinzolamide</p>
          </list-item>
        </list>
        <p>Cholinergic or parasympathomimetic agents reduce IOP by 20% to 25% by increasing the outflow of AH.<xref ref-type="bibr" rid="article-22264.r97">[97]</xref>&#x000a0;These agents are poorly tolerated and normally not considered first-line treatment.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pilocarpine</p>
          </list-item>
        </list>
        <p>
<bold>Systemic agents</bold>
</p>
        <p>These are used in the acute rise of IOP and angle-closure glaucoma or when topical medications are not tolerated.</p>
        <p>Carbonic anhydrase inhibitor:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Acetazolamide&#x000a0;</p>
          </list-item>
        </list>
        <p>Osmotic agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mannitol</p>
          </list-item>
          <list-item>
            <p>Glycerol</p>
          </list-item>
        </list>
        <p>
<bold>Laser Therapy for OAG</bold>
</p>
        <p>
<bold>Laser trabeculoplasty</bold>
</p>
        <p>The indications of laser trabeculoplasty include</p>
        <list list-type="bullet">
          <list-item>
            <p>The primary therapy for OAG</p>
          </list-item>
          <list-item>
            <p>Reduce the number of glaucoma drops</p>
          </list-item>
          <list-item>
            <p>Non-compliance or intolerance to medical therapy</p>
          </list-item>
          <list-item>
            <p>Failure of medical therapy as a less invasive alternative therapy compared to surgery</p>
          </list-item>
        </list>
        <p>The available methods of laser trabeculoplasty are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Argon laser trabeculoplasty: More than 75% of unoperated eyes initially have a good IOP reduction. Within 5 years, 30% to &#x0003e;50% of eyes need additional surgical management.<xref ref-type="bibr" rid="article-22264.r98">[98]</xref></p>
          </list-item>
          <list-item>
            <p>Selective laser trabeculoplasty: This uses Q-switched frequency-doubled Nd-YAG and is preferred to argon laser trabeculoplasty (ALT) because it utilizes less laser energy, reducing inflammation and less mechanical injury to the TM. The efficacy of selective laser trabeculoplasty is similar to ALT and possible to repeat over time.<xref ref-type="bibr" rid="article-22264.r99">[99]</xref></p>
          </list-item>
          <list-item>
            <p>Micropulse Diode Laser Trabeculoplasty: This laser is based on subthreshold micropulse laser techniques that aim to cause less damage and side effects to angle structures without compromising efficacy.<xref ref-type="bibr" rid="article-22264.r100">[100]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Diode laser cyclophotocoagulation&#x000a0;</bold>
</p>
        <p>This is a method for ablation of the ciliary processes that secrete aqueous.<xref ref-type="bibr" rid="article-22264.r101">[101]</xref>&#x000a0;Indications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Uncontrolled IOP in eyes with ambulatory vision if chances of surgical success are poor</p>
          </list-item>
          <list-item>
            <p>Management of refractory glaucoma</p>
          </list-item>
          <list-item>
            <p>Uncontrolled IOP in painful blind eyes or eyes with minimal visual potential</p>
          </list-item>
          <list-item>
            <p>Uncontrolled IOP with maximal medication after failed glaucoma surgery(ies)</p>
          </list-item>
        </list>
        <p>
<bold>Surgical Management of OAG</bold>
</p>
        <p>Indications for surgical management of glaucoma are:</p>
        <list list-type="bullet">
          <list-item>
            <p>IOP above target pressure or progression of visual fields and optic disc changes after compliance and maximally tolerable glaucoma medication</p>
          </list-item>
          <list-item>
            <p>To avoid excessive glaucoma drops</p>
          </list-item>
          <list-item>
            <p>Significant barriers to effective and regular medication: cost, compliance, physical disability, inconvenience, side effects, and psychosocial</p>
          </list-item>
          <list-item>
            <p>Primary therapy for advanced glaucoma requires low target IOP</p>
          </list-item>
          <list-item>
            <p>Patient preference over other options&#x000a0;<xref ref-type="bibr" rid="article-22264.r102">[102]</xref></p>
          </list-item>
        </list>
        <p>Surgical options include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Trabeculectomy: The success rate may vary from 31% to 88%, increasing with using mitomycin C or 5-fluorouracil (These agents, however, increase the risk of late-onset bleb leak, hypotony, and bleb-related infection.)<xref ref-type="bibr" rid="article-22264.r103">[103]</xref></p>
          </list-item>
          <list-item>
            <p>Glaucoma drainage device and valve: Molteno, Baerveldt, Ahmed&#x000a0;<xref ref-type="bibr" rid="article-22264.r104">[104]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Non-penetrating glaucoma surgery:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Deep sclerectomy</p>
              </list-item>
              <list-item>
                <p>Viscocanalostomy</p>
              </list-item>
              <list-item>
                <p>Canaloplasty&#x000a0;<xref ref-type="bibr" rid="article-22264.r105">[105]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Minimally invasive or micro-invasive glaucoma surgery <xref ref-type="bibr" rid="article-22264.r106">[106]</xref>&#x000a0;provides a conjunctiva-sparing surgery with an ab-interno approach to reduce IOP in mild to moderate glaucoma. The different approaches include:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Increasing trabecular outflow (Trabectome, iStent, Hydrus stent, gonioscopy-assisted transluminal trabeculotomy, excimer laser trabeculotomy)</p>
              </list-item>
              <list-item>
                <p>Suprachoroidal shunts (Cypass micro-stent)</p>
              </list-item>
              <list-item>
                <p>Reducing aqueous production (endocyclophotocoagulation)</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Subconjunctival filtration (XEN gel stent)<xref ref-type="bibr" rid="article-22264.r107">[107]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cyclocryotherapy</bold>
</p>
        <p>This is another method of cycloablation using cryotherapy, reserved for painful vision loss.<xref ref-type="bibr" rid="article-22264.r108">[108]</xref></p>
        <p>
<bold>Other options for painful blind eyes from glaucoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enucleation or evisceration&#x000a0;<xref ref-type="bibr" rid="article-22264.r109">[109]</xref></p>
          </list-item>
          <list-item>
            <p>Retrobulbar injection of absolute alcohol&#x000a0;<xref ref-type="bibr" rid="article-22264.r110">[110]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses should include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Optic nerve head diseases</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Physiological cup: Deep cup with healthy neuroretinal rim is seen with normal retinal nerve fiber layer thickness and no visual field defect; disc size may be large</p>
              </list-item>
              <list-item>
                <p>Optic disc drusen</p>
              </list-item>
              <list-item>
                <p>Optic disc coloboma</p>
              </list-item>
              <list-item>
                <p>Anomalous optic disc</p>
              </list-item>
              <list-item>
                <p>Tilted disc</p>
              </list-item>
              <list-item>
                <p>Ischemic optic neuropathy</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Retinal diseases causing similar visual field defects</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Branch retinal vein occlusion</p>
              </list-item>
              <list-item>
                <p>Branch retinal artery occlusion</p>
              </list-item>
              <list-item>
                <p>Retinitis pigmentosa</p>
              </list-item>
              <list-item>
                <p>Panretinal photocoagulation</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Central nervous system diseases</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Pituitary tumor: NRR is typically pale, pallor more than cupping, and bitemporal hemianopia exists, which respects the vertical line passing through the fixation (contrary to glaucoma, whose visual field respects the horizontal meridian)</p>
              </list-item>
              <list-item>
                <p>Intracranial hypotension due to cerebrospinal fluid shunts or other neurologic pathologies</p>
              </list-item>
              <list-item>
                <p>Foster Kennedy Syndrome</p>
              </list-item>
              <list-item>
                <p>Cerebrovascular pathologies or traumas</p>
              </list-item>
              <list-item>
                <p>Multiple sclerosis</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s12" sec-type="Staging">
        <title>Staging</title>
        <p>The Americal Academy of Ophthalmology's preferred practice pattern&#x000a0;<xref ref-type="bibr" rid="article-22264.r35">[35]</xref>&#x000a0;classifies the severity of glaucomatous damage into different categories:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: Definite optic disc or RNFL abnormalities consistent with glaucoma as detailed above and a normal visual field tested with standard automated perimetry (SAP) are seen.</p>
          </list-item>
          <list-item>
            <p>Moderate: Definite optic disc or RNFL abnormalities consistent with glaucoma, as detailed above, are seen, and visual field abnormalities in one hemifield are not within 5&#x000b0; of fixation as tested with SAP.</p>
          </list-item>
          <list-item>
            <p>Severe: Definite optic disc or RNFL abnormalities consistent with glaucoma as detailed above are seen, and visual field abnormalities in both hemifields or loss within 5&#x000b0; of fixation in at least one hemifield as tested with SAP.</p>
          </list-item>
          <list-item>
            <p>Indeterminate: Definite optic disc or RNFL abnormalities consistent with glaucoma, as detailed above, are seen, and the patient cannot perform visual field testing, has unreliable or uninterpretable visual field test results, or has not performed visual fields yet.</p>
          </list-item>
        </list>
        <p>Several different staging systems are recognized based on visual field damage,&#x000a0;<xref ref-type="bibr" rid="article-22264.r111">[111]</xref><xref ref-type="bibr" rid="article-22264.r112">[112]</xref>&#x000a0;optic disc cupping,<xref ref-type="bibr" rid="article-22264.r65">[65]</xref><xref ref-type="bibr" rid="article-22264.r113">[113]</xref>&#x000a0;and RNFL defects with OCT,<xref ref-type="bibr" rid="article-22264.r114">[114]</xref>&#x000a0;some of which are applicable in a routine clinical setting or clinical trials.<xref ref-type="bibr" rid="article-22264.r115">[115]</xref></p>
      </sec>
      <sec id="article-22264.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Advanced POAG may cause optic atrophy and no perception of light, though most OAG patients&#x000a0;will not lose vision in their lifetime. Risk factors for progression of OAG include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Old age</p>
          </list-item>
          <list-item>
            <p>Elevated IOP</p>
          </list-item>
          <list-item>
            <p>Increased cup-to-disc ratio or small optic rim area</p>
          </list-item>
          <list-item>
            <p>Beta peripapillary atrophy</p>
          </list-item>
          <list-item>
            <p>Disc hemorrhage</p>
          </list-item>
          <list-item>
            <p>Thin central corneal thickness</p>
          </list-item>
          <list-item>
            <p>Reduced corneal hysteresis</p>
          </list-item>
          <list-item>
            <p>Low ocular perfusion pressure</p>
          </list-item>
          <list-item>
            <p>Poor compliance with therapy</p>
          </list-item>
          <list-item>
            <p>Pseudoexfoliation&#x000a0;<xref ref-type="bibr" rid="article-22264.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>In 10 years, the cumulative probability of end-stage glaucoma in at least one eye in untreated cases was shown to be 35% in study results.<xref ref-type="bibr" rid="article-22264.r116">[116]</xref></p>
      </sec>
      <sec id="article-22264.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of glaucoma include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Blindness: usually painless</p>
          </list-item>
          <list-item>
            <p>Painful blind eye or absolute glaucoma: OAG predisposes to central retinal venous occlusion,&#x000a0;leading to neovascular glaucoma and painful blind eye&#x000a0;<xref ref-type="bibr" rid="article-22264.r117">[117]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>Screening and management of OAG are typically performed by the following healthcare professionals that deal with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ophthalmology, comprehensive general</p>
          </list-item>
          <list-item>
            <p>Ophthalmology, glaucoma specialist</p>
          </list-item>
          <list-item>
            <p>Optometry with special training in ocular hypertension and glaucoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22264.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Glaucoma is a preventable cause of blindness, making patient education crucial in managing and preventing the progression of OAG. Effective and successful treatment of OAG can prevent the evolution of optic nerve atrophy and&#x000a0;preserve&#x000a0;patient vision.<xref ref-type="bibr" rid="article-22264.r118">[118]</xref> However, patient adherence and compliance with medical therapy are notoriously difficult.<xref ref-type="bibr" rid="article-22264.r119">[119]</xref>&#x000a0;Treatment regimens require daily treatment to control&#x000a0;IOP, and this can be a challenging task for patients for the rest of their lives.<xref ref-type="bibr" rid="article-22264.r120">[120]</xref></p>
        <p>The nature of medication regimens requiring daily dosage is challenging for many patients, and inconsistent medication administration&#x000a0;does not adequately control IOP. Some patients will attempt to use their drops daily but fail to deliver the medications to their eyes. Thus, the medication will not be absorbed, specifically in at-risk older populations. Over a prolonged time frame, failure to adhere to daily drops or oral medication will increase the likelihood of progression to blindness.<xref ref-type="bibr" rid="article-22264.r121">[121]</xref></p>
        <p>Studies have confirmed an inverse relationship between the number and frequency of dosage and patient adherence concerning glaucoma treatment. One study looked into the reasons why patients struggled to adhere to their regimens, and the most commonly cited reasons were forgetfulness (30%), other priorities (11%), lack of information (9%), emotional factors (7%) with 27% of individuals surveyed not providing a reason.&#x000a0;</p>
        <p>Previous studies have shown that improved&#x000a0;patient education regarding disease processes and the rationale behind treatment regimens&#x000a0;makes&#x000a0;patients consistently more likely to&#x000a0;adhere to their prescribed medication regimens.&#x000a0;A 2018 study found that physician-centric multifaceted informational and educational mailings were ineffective in improving adherence to IOP-lowering treatment in older patients with glaucoma.<xref ref-type="bibr" rid="article-22264.r122">[122]</xref><xref ref-type="bibr" rid="article-22264.r123">[123]</xref></p>
        <p>Educating patients is crucial for effective glaucoma management, but the best way to provide such education is still unknown. Interestingly, other studies have found no link between medication adherence and side effects and that side effects are unlikely to discourage patients. One of the tricky aspects of glaucoma is that patients often&#x000a0;do not experience any symptoms until it is too late. An interprofessional approach is required to tackle this issue, as not all patients visit their ophthalmologist regularly. Therefore, nurses, therapists, social care workers, and primary care clinicians should be the first line of defense.</p>
      </sec>
      <sec id="article-22264.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure, potentially leading to optic nerve damage and vision loss. As the most common type of glaucoma, it often develops gradually without noticeable symptoms until advanced stages. Regular eye exams, including measuring intraocular pressure and assessing optic nerve health, are crucial for early detection. Treatment aims to lower intraocular pressure through medications, laser therapy, or surgery. Clinicians should emphasize the importance of adherence to prescribed treatments and routine follow-up appointments. Given its asymptomatic nature, raising awareness among at-risk populations, such as individuals&#x000a0;older than 40 or those with a family history, is essential for early intervention and optimal management of open-angle glaucoma.</p>
        <p>If untreated, OAG leads to progressive loss of peripheral vision followed by central visual field loss. Due to its chronicity, the condition is best managed by an interprofessional team that provides patient education and ensures that daily dosing is maintained. The best outcomes occur when the clinician, ophthalmic specialty-trained nurse, and pharmacist work together to educate and support the patient.</p>
      </sec>
      <sec id="article-22264.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22264&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22264">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/open-angle-glaucoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22264">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22264/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22264">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22264.s19">
        <fig id="article-22264.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Classification of open-angle glaucoma. Contributed by Marco Zeppieri, MD, PhD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OAG" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s20">
        <fig id="article-22264.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Visual field and Optical Coherence Tomography (OCT) results in a patients with open-angle glaucoma. Superior visual field defects correspond to inferior retinal nerve fiber layer thinning with OCT. Contributed by Marco Zeppieri, MD, PhD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Glaucoma__figure__StatPearls__Feb__2023" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s21">
        <fig id="article-22264.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Glaucomatous Optic Nerve Head Showing Inferotemporal Retinal Nerve Fiber Layer Defect. Increased intraocular pressure&#x000a0;can result in reduced blood supply to the optic nerve fibers, resulting in subtle ischemic injury. Contributed by K Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="poag" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s22">
        <fig id="article-22264.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Optic Nerve Cup-to-Disc Ratio of 0.75.&#x000a0;A cup-to-disc ratio greater than 0.5 is often associated with glaucoma, and initial loss is typically observed in the inferotemporal and superotemporal poles of the optic disc. Contributed by AS Huang, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2021-10-04__at__5.06.26__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s23">
        <fig id="article-22264.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Left Eye Glaucomatous Visual Field Changes.&#x000a0;This image displays the results of a visual field test indicating characteristic changes associated with glaucoma in the left eye, as observed on perimetry. Contributed by S Shah, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1628623000792" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s24">
        <fig id="article-22264.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Normal visual field and Optical Coherence Tomography (OCT) results in a patients with ocular hypertension (OHT). Contributed by Marco Zeppieri, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CV__e__OCT__in__OHT__figure__StatPearls__Feb__2023" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s25">
        <fig id="article-22264.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Goldmann Applanation Tonometer (GAT) mounted on a slit-lamp. Contributed by Marco Zeppieri, MD, PhD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22264.s26">
        <fig id="article-22264.image.f8" position="float" orientation="portrait">
          <caption>
            <p>A tip with a split-image prism (A) is used with the Goldmann Applanation Tonometer (GAT), which is mounted on a slit-lamp (B). Filtered cobalt blue light is used during the measurement. The tip is positioned on the center of the eye to gently flatten the cornea (C). Contributed by Marco Zeppieri, MD, PhD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22264.s27">
        <title>References</title>
        <ref id="article-22264.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma.</article-title>
            <source>Am Fam Physician</source>
            <year>2016</year>
            <month>Apr</month>
            <day>15</day>
            <volume>93</volume>
            <issue>8</issue>
            <fpage>668</fpage>
            <page-range>668-74</page-range>
            <pub-id pub-id-type="pmid">27175839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>DYL</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Normal-tension glaucoma: Current concepts and approaches-A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-259</page-range>
            <pub-id pub-id-type="pmid">35040248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kastner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Advanced glaucoma at diagnosis: current perspectives.</article-title>
            <source>Eye (Lond)</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-128</page-range>
            <pub-id pub-id-type="pmid">31740802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parajuli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Ocular Hypertension in Patients Above 40 Years of Age.</article-title>
            <source>Nepal J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>27</issue>
            <fpage>140</fpage>
            <page-range>140-143</page-range>
            <pub-id pub-id-type="pmid">35996922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Kass</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>What We Have Learned From the Ocular Hypertension Treatment Study.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2018</year>
            <month>May</month>
            <volume>189</volume>
            <fpage>xxiv</fpage>
            <page-range>xxiv-xxvii</page-range>
            <pub-id pub-id-type="pmid">29501371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veeraraghavan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Adult Eye Conditions: Primary Open-Angle Glaucoma and Cataract.</article-title>
            <source>FP Essent</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>519</volume>
            <fpage>19</fpage>
            <page-range>19-23</page-range>
            <pub-id pub-id-type="pmid">35947132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology and treatment of glaucoma: a review.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>May</month>
            <day>14</day>
            <volume>311</volume>
            <issue>18</issue>
            <fpage>1901</fpage>
            <page-range>1901-11</page-range>
            <pub-id pub-id-type="pmid">24825645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association of WDR36 polymorphisms with primary open angle glaucoma: A systematic review and meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>26</issue>
            <fpage>e7291</fpage>
            <pub-id pub-id-type="pmid">28658128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monemi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spaeth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>DaSilva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Popinchalk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ilitchev</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liebmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>H&#x000e9;on</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crick</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarfarazi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1.</article-title>
            <source>Hum Mol Genet</source>
            <year>2005</year>
            <month>Mar</month>
            <day>15</day>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>725</fpage>
            <page-range>725-33</page-range>
            <pub-id pub-id-type="pmid">15677485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorleifsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Masson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Helgason</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeWan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sigurdsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jonasdottir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudjonsson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Gudmundsdottir</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Southgate</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burdon</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Gottfredsdottir</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Aldred</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sveinsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Macgregor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Cree</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macleod</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ennis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Karwatowski</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Thordarson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wadelius</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Trembath</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hoh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jonasson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma.</article-title>
            <source>Nat Genet</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>906</fpage>
            <page-range>906-9</page-range>
            <pub-id pub-id-type="pmid">20835238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borr&#x000e1;s</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gene expression in the trabecular meshwork and the influence of intraocular pressure.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>435</fpage>
            <page-range>435-63</page-range>
            <pub-id pub-id-type="pmid">12742391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Loomis</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yaspan</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Abdrabou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Budenz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Delbono</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Gaasterland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaasterland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grosskreutz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lichter</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McCarty</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moroi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Realini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Schuman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vollrath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wollstein</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zack</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Allingham</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Pericak-Vance</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Haines</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>155</volume>
            <issue>2</issue>
            <fpage>342</fpage>
            <page-range>342-353.e5</page-range>
            <pub-id pub-id-type="pmid">23111177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nunes</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Ananina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Zanchin</surname>
                <given-names>NIT</given-names>
              </name>
              <name>
                <surname>de Vasconcellos</surname>
                <given-names>JPC</given-names>
              </name>
              <name>
                <surname>de Melo</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Investigation of CAV1/CAV2 rs4236601 and CDKN2B-AS1 rs2157719 in primary open-angle glaucoma patients from Brazil.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-199</page-range>
            <pub-id pub-id-type="pmid">29111846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burdon</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Macgregor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chidlow</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Danoy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Casson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henders</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Souzeau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rochtchina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nyholt</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1.</article-title>
            <source>Nat Genet</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>574</fpage>
            <page-range>574-8</page-range>
            <pub-id pub-id-type="pmid">21532571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Optineurin E50K triggers BDNF deficiency-mediated mitochondrial dysfunction in retinal photoreceptor cell line.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>503</volume>
            <issue>4</issue>
            <fpage>2690</fpage>
            <page-range>2690-2697</page-range>
            <pub-id pub-id-type="pmid">30100066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Knockdown of LOXL1 inhibits TGF-&#x003b2;1-induced proliferation and fibrogenesis of hepatic stellate cells by inhibition of Smad2/3 phosphorylation.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>107</volume>
            <fpage>1728</fpage>
            <page-range>1728-1735</page-range>
            <pub-id pub-id-type="pmid">30257391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zenkel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasutto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hoja</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Liravi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gusek-Schneider</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;del</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Posttranscriptional Regulation of LOXL1 Expression Via Alternative Splicing and Nonsense-Mediated mRNA Decay as an Adaptive Stress Response.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>58</volume>
            <issue>13</issue>
            <fpage>5930</fpage>
            <page-range>5930-5940</page-range>
            <pub-id pub-id-type="pmid">29164236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guven Yilmaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palamar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ilim</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aykut</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozkinay</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Yagci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Association of Lysyl Oxidase-like 1 Gene Polymorphism in Turkish Patients With Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>684</fpage>
            <page-range>684-685</page-range>
            <pub-id pub-id-type="pmid">28369001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Burdon</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Ronci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voelcker</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Biological effect of LOXL1 coding variants associated with pseudoexfoliation syndrome.</article-title>
            <source>Exp Eye Res</source>
            <year>2016</year>
            <month>May</month>
            <volume>146</volume>
            <fpage>212</fpage>
            <page-range>212-223</page-range>
            <pub-id pub-id-type="pmid">26997634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>Chiariglione</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arch</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Whole-exome sequencing study identifies rare variants and genes associated with intraocular pressure and glaucoma.</article-title>
            <source>Nat Commun</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>7376</fpage>
            <pub-id pub-id-type="pmid">36450729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mabuchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakurada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoneyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kashiwagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamagata</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Takamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shiga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Araie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genetic variants associated with glaucomatous visual field loss in primary open-angle glaucoma.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>20744</fpage>
            <pub-id pub-id-type="pmid">36456827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zukerman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oddone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Siesky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verticchio Vercellin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciulla</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma Heritability: Molecular Mechanisms of Disease.</article-title>
            <source>Genes (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>27</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">34440309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <day>02</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>13762</fpage>
            <pub-id pub-id-type="pmid">34215769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malihi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moura Filho</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Sit</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>134</fpage>
            <page-range>134-141</page-range>
            <pub-id pub-id-type="pmid">24823760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Broman</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>The number of people with glaucoma worldwide in 2010 and 2020.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>262</fpage>
            <page-range>262-7</page-range>
            <pub-id pub-id-type="pmid">16488940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Distelhorst</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Open-angle glaucoma.</article-title>
            <source>Am Fam Physician</source>
            <year>2003</year>
            <month>May</month>
            <day>01</day>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>1937</fpage>
            <page-range>1937-44</page-range>
            <pub-id pub-id-type="pmid">12751655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfs</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Klaver</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ramrattan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>116</volume>
            <issue>12</issue>
            <fpage>1640</fpage>
            <page-range>1640-5</page-range>
            <pub-id pub-id-type="pmid">9869795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birhanu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tegegne</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Predictors for elevation of Intraocular Pressure (IOP) on glaucoma patients; a retrospective cohort study design.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2022</year>
            <month>Jun</month>
            <day>07</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>254</fpage>
            <pub-id pub-id-type="pmid">35672680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Degree of Myopia and Glaucoma Risk: A Dose-Response Meta-analysis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>236</volume>
            <fpage>107</fpage>
            <page-range>107-119</page-range>
            <pub-id pub-id-type="pmid">34648776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maruyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Omi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamuro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tashiro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sotozono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Novel Vertical Cup-to-Disc Classification to Identify Normal Eyes That Maintain Non-Glaucoma Status: A 10-Year Longitudinal Study.</article-title>
            <source>J Glaucoma</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-132</page-range>
            <pub-id pub-id-type="pmid">36001508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kee</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based understanding of disc hemorrhage in glaucoma.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-422</page-range>
            <pub-id pub-id-type="pmid">32949554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miglior</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Corneal thickness and functional damage in patients with ocular hypertension.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-201</page-range>
            <pub-id pub-id-type="pmid">15812759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Jeoung</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Ocular Perfusion Pressure and the Risk of Open-Angle Glaucoma: Systematic Review and Meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Jun</month>
            <day>22</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>10056</fpage>
            <pub-id pub-id-type="pmid">32572072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leske</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Hennis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Honkanen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nemesure</surname>
                <given-names>B</given-names>
              </name>
              <collab>BESs Study Group</collab>
            </person-group>
            <article-title>Risk factors for incident open-angle glaucoma: the Barbados Eye Studies.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-93</page-range>
            <pub-id pub-id-type="pmid">17629563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prum</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gedde</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mansberger</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moroi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Herndon</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Primary Open-Angle Glaucoma Preferred Practice Pattern(&#x000ae;) Guidelines.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>P41</fpage>
            <page-range>P41-P111</page-range>
            <pub-id pub-id-type="pmid">26581556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Elze</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zebardast</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Association Between Diabetes, Diabetic Retinopathy, and Glaucoma.</article-title>
            <source>Curr Diab Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>08</day>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">34495413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mayama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Asaoka</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Do pattern deviation values accurately estimate glaucomatous visual field damage in eyes with glaucoma and cataract?</article-title>
            <source>Br J Ophthalmol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>1240</fpage>
            <page-range>1240-4</page-range>
            <pub-id pub-id-type="pmid">25795915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gramer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Gramer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>13</issue>
            <fpage>7999</fpage>
            <page-range>7999-8007</page-range>
            <pub-id pub-id-type="pmid">26720447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baneke</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Aubry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Plant</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>The role of intracranial pressure in glaucoma and therapeutic implications.</article-title>
            <source>Eye (Lond)</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-191</page-range>
            <pub-id pub-id-type="pmid">31776450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogden</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mikelberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khosrow-Khavar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mansournia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The association between hormonal contraceptive use and glaucoma in women of reproductive age.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>4780</fpage>
            <page-range>4780-4785</page-range>
            <pub-id pub-id-type="pmid">34159623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno-Monta&#x000f1;&#x000e9;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x000e1;ndara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gutierrez-Ruiz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moreno-Galarraga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruiz-Canela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bes-Rastrollo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Fernandez-Montero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Healthy Lifestyle Score and Incidence of Glaucoma: The Sun Project.</article-title>
            <source>Nutrients</source>
            <year>2022</year>
            <month>Feb</month>
            <day>12</day>
            <volume>14</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35215429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zack</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pease</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kerrigan-Baumrind</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kerrigan</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>3460</fpage>
            <page-range>3460-6</page-range>
            <pub-id pub-id-type="pmid">11006239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Phototransduction in ganglion-cell photoreceptors.</article-title>
            <source>Pflugers Arch</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>454</volume>
            <issue>5</issue>
            <fpage>849</fpage>
            <page-range>849-55</page-range>
            <pub-id pub-id-type="pmid">17351786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hattar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Berson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Central projections of melanopsin-expressing retinal ganglion cells in the mouse.</article-title>
            <source>J Comp Neurol</source>
            <year>2006</year>
            <month>Jul</month>
            <day>20</day>
            <volume>497</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-49</page-range>
            <pub-id pub-id-type="pmid">16736474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan-Davies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Aspinall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Three dimensional analysis of the lamina cribrosa in glaucoma.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>88</volume>
            <issue>10</issue>
            <fpage>1299</fpage>
            <page-range>1299-304</page-range>
            <pub-id pub-id-type="pmid">15377555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Addicks</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Regional differences in the structure of the lamina cribrosa and their relation to glaucomatous optic nerve damage.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1981</year>
            <month>Jan</month>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-43</page-range>
            <pub-id pub-id-type="pmid">7458737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan-Davies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Aspinall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Measurement of a novel optic disc topographic parameter, "spikiness", in glaucoma.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>238</volume>
            <issue>8</issue>
            <fpage>669</fpage>
            <page-range>669-76</page-range>
            <pub-id pub-id-type="pmid">11011687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dielemans</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vingerling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wolfs</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grobbee</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study.</article-title>
            <source>Ophthalmology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>101</volume>
            <issue>11</issue>
            <fpage>1851</fpage>
            <page-range>1851-5</page-range>
            <pub-id pub-id-type="pmid">7800368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Microcirculation of optic nerve head and glaucoma].</article-title>
            <source>Zhonghua Yan Ke Za Zhi</source>
            <year>2016</year>
            <month>Jun</month>
            <day>11</day>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>466</fpage>
            <page-range>466-70</page-range>
            <pub-id pub-id-type="pmid">27373574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fortune</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reynaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hardin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sigal</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Burgoyne</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Experimental Glaucoma Causes Optic Nerve Head Neural Rim Tissue Compression: A Potentially Important Mechanism of Axon Injury.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2016</year>
            <month>Aug</month>
            <day>01</day>
            <volume>57</volume>
            <issue>10</issue>
            <fpage>4403</fpage>
            <page-range>4403-11</page-range>
            <pub-id pub-id-type="pmid">27564522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buffault</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brignole-Baudouin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The trabecular meshwork: Structure, function and clinical implications. A review of the literature.</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>e217</fpage>
            <page-range>e217-e230</page-range>
            <pub-id pub-id-type="pmid">32561029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zukerman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vercellin</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Siesky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Ciulla</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations.</article-title>
            <source>Genes (Basel)</source>
            <year>2020</year>
            <month>Dec</month>
            <day>31</day>
            <volume>12</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33396423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moghimi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liebmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Girkin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Zangwill</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Association of Intraocular Pressure With Retinal Nerve Fiber Layer Thinning in Patients With Glaucoma.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>140</volume>
            <issue>12</issue>
            <fpage>1209</fpage>
            <page-range>1209-1216</page-range>
            <pub-id pub-id-type="pmid">36301523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Dasari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puttaiah</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Moghimi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Webers</surname>
                <given-names>CAB</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Optical Microangiography and Progressive Retinal Nerve Fiber Layer Loss in Primary Open Angle Glaucoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>233</volume>
            <fpage>171</fpage>
            <page-range>171-179</page-range>
            <pub-id pub-id-type="pmid">34320375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Addicks</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Maumenee</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>635</fpage>
            <page-range>635-49</page-range>
            <pub-id pub-id-type="pmid">6164357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>C&#x00103;lug&#x00103;ru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>C&#x00103;lug&#x00103;ru</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Secondary open-angle pigmentary glaucoma resulting from pseudophakia. Case report.</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2016</year>
            <season>Apr-Jun</season>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-130</page-range>
            <pub-id pub-id-type="pmid">29450335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pires</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mariano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Corneal Elevation Topography in Primary Open Angle Glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>e41</fpage>
            <page-range>e41-e45</page-range>
            <pub-id pub-id-type="pmid">27599178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alamri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alkatan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aljadaan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Traumatic Ghost Cell Glaucoma with Successful Resolution of Corneal Blood Staining Following Pars Plana Vitrectomy.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2016</year>
            <season>Jul-Sep</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-3</page-range>
            <pub-id pub-id-type="pmid">27555716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r59">
          <label>59</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Pigment Dispersion Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35593820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pigment dispersion syndrome: A brief overview.</article-title>
            <source>J Clin Transl Res</source>
            <year>2022</year>
            <month>Oct</month>
            <day>31</day>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>344</fpage>
            <page-range>344-350</page-range>
            <pub-id pub-id-type="pmid">36518550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padhy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alone</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Is pseudoexfoliation glaucoma a neurodegenerative disorder?</article-title>
            <source>J Biosci</source>
            <year>2021</year>
            <volume>46</volume>
            <pub-id pub-id-type="pmid">34785624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMenamin</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Ultrastructural pathology of melanomalytic glaucoma.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1986</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>895</fpage>
            <page-range>895-906</page-range>
            <pub-id pub-id-type="pmid">3801367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r63">
          <label>63</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feroze</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khazaeni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Steroid-Induced Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">28613653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Khawaja</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma in Adults-Screening, Diagnosis, and Management: A Review.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jan</month>
            <day>12</day>
            <volume>325</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-174</page-range>
            <pub-id pub-id-type="pmid">33433580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Optic disc damage staging system.</article-title>
            <source>J Glaucoma</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>442</fpage>
            <page-range>442-9</page-range>
            <pub-id pub-id-type="pmid">20051883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Triads in Ophthalmology: A Comprehensive Review.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2017</year>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-250</page-range>
            <pub-id pub-id-type="pmid">26148300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maupin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arnould</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Seydou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Binquet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Creuzot-Garcher</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Accuracy of the ISNT rule and its variants for differentiating glaucomatous from normal eyes in a population-based study.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>104</volume>
            <issue>10</issue>
            <fpage>1412</fpage>
            <page-range>1412-1417</page-range>
            <pub-id pub-id-type="pmid">31959590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollands</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hollands</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simel</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jinapriya</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>May</month>
            <day>15</day>
            <volume>309</volume>
            <issue>19</issue>
            <fpage>2035</fpage>
            <page-range>2035-42</page-range>
            <pub-id pub-id-type="pmid">23677315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Susanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vessani</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Staging glaucoma patient: why and how?</article-title>
            <source>Open Ophthalmol J</source>
            <year>2009</year>
            <month>Sep</month>
            <day>17</day>
            <volume>3</volume>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">19834563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalyani</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Bharucha</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of diagnostic ability of standard automated perimetry, short wavelength automated perimetry, retinal nerve fiber layer thickness analysis and ganglion cell layer thickness analysis in early detection of glaucoma.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1108</fpage>
            <page-range>1108-1112</page-range>
            <pub-id pub-id-type="pmid">33913843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sampaolesi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Pulsar perimetry in the diagnosis of early glaucoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-12</page-range>
            <pub-id pub-id-type="pmid">19800607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sampaolesi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Learning effect and test-retest variability of pulsar perimetry.</article-title>
            <source>J Glaucoma</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>230</fpage>
            <page-range>230-7</page-range>
            <pub-id pub-id-type="pmid">22027935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Rarebit perimetry in normal subjects: test-retest variability, learning effect, normative range, influence of optical defocus, and cataract extraction.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>5320</fpage>
            <page-range>5320-31</page-range>
            <pub-id pub-id-type="pmid">17962489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Probing glaucoma visual damage by rarebit perimetry.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-4</page-range>
            <pub-id pub-id-type="pmid">15665349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Felletti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Visual field testing with the new Humphrey Matrix: a comparison between the FDT N-30 and Matrix N-30-F tests.</article-title>
            <source>Acta Ophthalmol Scand</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-6</page-range>
            <pub-id pub-id-type="pmid">16704697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastropasqua</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carpineto</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ciancaglini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Antonio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Humphrey matrix frequency doubling technology perimetry and optical coherence tomography measurement of the retinal nerve fiber layer thickness in both normal and ocular hypertensive subjects.</article-title>
            <source>J Glaucoma</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>328</fpage>
            <page-range>328-35</page-range>
            <pub-id pub-id-type="pmid">16865011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harwerth</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Visual field defects and retinal ganglion cell losses in patients with glaucoma.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>124</volume>
            <issue>6</issue>
            <fpage>853</fpage>
            <page-range>853-9</page-range>
            <pub-id pub-id-type="pmid">16769839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harwerth</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Carter-Dawson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Ganglion cell losses underlying visual field defects from experimental glaucoma.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>2242</fpage>
            <page-range>2242-50</page-range>
            <pub-id pub-id-type="pmid">10476789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aizawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Omodaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kunikata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yasui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Preperimetric Glaucoma Prospective Study (PPGPS): Predicting Visual Field Progression With Basal Optic Nerve Head Blood Flow in Normotensive PPG Eyes.</article-title>
            <source>Transl Vis Sci Technol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">29372113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r80">
          <label>80</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bader</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <chapter-title>Tonometry</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29630277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How to Measure Intraocular Pressure: An Updated Review of Various Tonometers.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Aug</month>
            <day>27</day>
            <volume>10</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">34501306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r82">
          <label>82</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Applanation Tonometry</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">35881737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Edgar</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inter-optometrist variability of IOP measurement for modern tonometers and their agreement with Goldmann Applanation Tonometry.</article-title>
            <source>Clin Exp Optom</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>602</fpage>
            <page-range>602-610</page-range>
            <pub-id pub-id-type="pmid">33689641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biswas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Relationship between Diurnal Variation in Intraocular Pressure and Central Corneal Power.</article-title>
            <source>Optom Vis Sci</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-104</page-range>
            <pub-id pub-id-type="pmid">36705719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belovay</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The thick and thin of the central corneal thickness in glaucoma.</article-title>
            <source>Eye (Lond)</source>
            <year>2018</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>915</fpage>
            <page-range>915-923</page-range>
            <pub-id pub-id-type="pmid">29445115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Buhrmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The definition and classification of glaucoma in prevalence surveys.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-42</page-range>
            <pub-id pub-id-type="pmid">11815354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r87">
          <label>87</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khazaeni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khazaeni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Angle-Closure Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">28613607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Correlation of retinal nerve fiber layer thickness with perimetric staging in primary open-angle glaucoma - A cross-sectional study.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2022</year>
            <season>Jan-Apr</season>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-42</page-range>
            <pub-id pub-id-type="pmid">35388245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kansal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pintwala</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hutnik</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography for glaucoma diagnosis: An evidence based meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>e0190621</fpage>
            <pub-id pub-id-type="pmid">29300765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sihota</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Angmo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramaswamy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dada</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>495</fpage>
            <page-range>495-505</page-range>
            <pub-id pub-id-type="pmid">29582808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sit</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pruet</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Personalizing Intraocular Pressure: Target Intraocular Pressure in the Setting of 24-Hour Intraocular Pressure Monitoring.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">26886115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaharia</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Dumitrescu</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Radu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogoz</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Adherence to Therapy in Glaucoma Treatment-A Review.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>22</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35455630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holl&#x000f3;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsanos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boboridis</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Irkec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konstas</surname>
                <given-names>AGP</given-names>
              </name>
            </person-group>
            <article-title>Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.</article-title>
            <source>Drugs</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-64</page-range>
            <pub-id pub-id-type="pmid">29196953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vajaranant</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Dikopf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Brimonidine tartrate for the treatment of glaucoma.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-122</page-range>
            <pub-id pub-id-type="pmid">30407890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skov</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rives</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Freiberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kolko</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2022</year>
            <month>May</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-261</page-range>
            <pub-id pub-id-type="pmid">34128326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Supuran</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Altamimi</surname>
                <given-names>ASA</given-names>
              </name>
              <name>
                <surname>Carta</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019.</article-title>
            <source>Expert Opin Ther Pat</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>781</fpage>
            <page-range>781-792</page-range>
            <pub-id pub-id-type="pmid">31596641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r97">
          <label>97</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Panarese</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Moshirfar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Pilocarpine (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">32310588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greslechner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Laser Trabeculoplasty in Modern Glaucoma Therapy - a Review].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>236</volume>
            <issue>10</issue>
            <fpage>1192</fpage>
            <page-range>1192-1200</page-range>
            <pub-id pub-id-type="pmid">29642265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landers</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Selective laser trabeculoplasty: A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1102</fpage>
            <page-range>1102-1110</page-range>
            <pub-id pub-id-type="pmid">34331388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>SWY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JKW</given-names>
              </name>
            </person-group>
            <article-title>Micropulse laser for the treatment of glaucoma: A literature review.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>486</fpage>
            <page-range>486-497</page-range>
            <pub-id pub-id-type="pmid">30639207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Souissi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Mer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Metge</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Portmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An update on continuous-wave cyclophotocoagulation (CW-CPC) and micropulse transscleral laser treatment (MP-TLT) for adult and paediatric refractory glaucoma.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>e621</fpage>
            <page-range>e621-e653</page-range>
            <pub-id pub-id-type="pmid">33222409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The surgical management of glaucoma: A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-231</page-range>
            <pub-id pub-id-type="pmid">35037376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fernie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kernohan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Homer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shabaninejad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sparrow</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Garway-Heath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Norrie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>MacLennan</surname>
                <given-names>G</given-names>
              </name>
              <collab>TAGS Study Group</collab>
            </person-group>
            <article-title>Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS).</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>May</month>
            <day>12</day>
            <volume>373</volume>
            <fpage>n1014</fpage>
            <pub-id pub-id-type="pmid">33980505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muralidharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ichhpujani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Quality of life in glaucoma patients: Comparison of medical therapy, trabeculectomy, and glaucoma drainage device surgery.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>4206</fpage>
            <page-range>4206-4211</page-range>
            <pub-id pub-id-type="pmid">36453315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Non-penetrating glaucoma surgery for advanced open-angle glaucoma.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>256</volume>
            <issue>8</issue>
            <fpage>1479</fpage>
            <pub-id pub-id-type="pmid">29911272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richter</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Minimally invasive glaucoma surgery: current status and future prospects.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>189</fpage>
            <page-range>189-206</page-range>
            <pub-id pub-id-type="pmid">26869753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>ICF</given-names>
              </name>
              <name>
                <surname>van de Wijdeven</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wyss</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>HJM</given-names>
              </name>
              <name>
                <surname>den Toonder</surname>
                <given-names>JMJ</given-names>
              </name>
            </person-group>
            <article-title>Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions.</article-title>
            <source>Eye (Lond)</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>3202</fpage>
            <page-range>3202-3221</page-range>
            <pub-id pub-id-type="pmid">34127842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miljkovi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>&#x0010c;anadanovi&#x00107;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Davidovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ljikar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vasin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>EFFICACY OF CYCLOCRYOTHERAPY AND TRANSSCLERAL DIODE LASER CYCLOPHOTOCOAGULATION IN THE MANAGEMENT OF REFRACTORY GLAUCOMA.</article-title>
            <source>Acta Clin Croat</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-177</page-range>
            <pub-id pub-id-type="pmid">34744265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowanz</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Wawer Matos</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Doulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rokohl</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Heindl</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>[Evisceration, enucleation and exenteration-Indications, techniques, and postoperative care].</article-title>
            <source>Ophthalmologie</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-138</page-range>
            <pub-id pub-id-type="pmid">36635593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galindo-Ferreiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akaishi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khandekar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al Dosairi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dufaileej</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Salem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galvez-Ruiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Craven</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Retrobulbar Injections for Blind Painful Eyes: A Comparative Study of Retrobulbar Alcohol Versus Chlorpromazine.</article-title>
            <source>J Glaucoma</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>886</fpage>
            <page-range>886-890</page-range>
            <pub-id pub-id-type="pmid">27814327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spaeth</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>The stages of glaucoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>141</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <page-range>147-8</page-range>
            <pub-id pub-id-type="pmid">16386990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Estimating glaucomatous anatomical damage by computerized automated perimetry.</article-title>
            <source>Acta Ophthalmol Scand Suppl</source>
            <year>1997</year>
            <issue>224</issue>
            <fpage>28</fpage>
            <page-range>28-9</page-range>
            <pub-id pub-id-type="pmid">9589720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spaeth</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Junk</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Grigorian</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Henderer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Systems for staging the amount of optic nerve damage in glaucoma: a critical review and new material.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-315</page-range>
            <pub-id pub-id-type="pmid">16818081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>OCT Glaucoma Staging System: a new method for retinal nerve fiber layer damage classification using spectral-domain OCT.</article-title>
            <source>Eye (Lond)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-119</page-range>
            <pub-id pub-id-type="pmid">28776589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sample</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zangwill</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Girkin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Liebmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Racette</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Comparison of visual field severity classification systems for glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2012</year>
            <season>Oct-Nov</season>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>551</fpage>
            <page-range>551-61</page-range>
            <pub-id pub-id-type="pmid">21878817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Progression of visual field loss in untreated glaucoma patients and suspects in St Lucia, West Indies.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>2002</year>
            <volume>100</volume>
            <fpage>365</fpage>
            <page-range>365-410</page-range>
            <pub-id pub-id-type="pmid">12545702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mokhles</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schouten</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tuulonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Webers</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma blindness at the end of life.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-11</page-range>
            <pub-id pub-id-type="pmid">28102642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiscella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kamble</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bunniran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uribe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chandwani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1284</fpage>
            <page-range>1284-1294</page-range>
            <pub-id pub-id-type="pmid">29848186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Compliance and adherence in glaucoma management.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>59 Suppl</volume>
            <issue>Suppl1</issue>
            <fpage>S93</fpage>
            <page-range>S93-6</page-range>
            <pub-id pub-id-type="pmid">21150041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive perspective on patient adherence to topical glaucoma therapy.</article-title>
            <source>Ophthalmology</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>116</volume>
            <issue>11 Suppl</issue>
            <fpage>S30</fpage>
            <page-range>S30-6</page-range>
            <pub-id pub-id-type="pmid">19837258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>5052</fpage>
            <page-range>5052-7</page-range>
            <pub-id pub-id-type="pmid">17962457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olthoff</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Schouten</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>van de Borne</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Webers</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>953</fpage>
            <page-range>953-61</page-range>
            <pub-id pub-id-type="pmid">15885795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22264.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osterberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Blaschke</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Adherence to medication.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Aug</month>
            <day>04</day>
            <volume>353</volume>
            <issue>5</issue>
            <fpage>487</fpage>
            <page-range>487-97</page-range>
            <pub-id pub-id-type="pmid">16079372</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
